Stockscreener 앱 받기
56.23
2.82%
1.54
시간 외 거래:
56.11
-0.12
-0.21%
전일 마감가:
$54.69
열려 있는:
$54.6
하루 거래량:
6.97M
Relative Volume:
1.94
시가총액:
$24.93B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
29.45
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+6.17%
1개월 성능:
+4.40%
6개월 성능:
+43.37%
1년 성능:
+59.43%
1일 변동 폭
$54.60
$56.29
1주일 범위
$52.89
$56.29
52주 변동 폭
$34.08
$56.50
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
56.23 | 24.24B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Insider Sell Alert: Marshall Urist Sells Shares of Royalty Pharm - GuruFocus
Royalty Pharma EVP Hite sells $8.16m in shares - Investing.com UK
Form 4 Royalty Pharma Plc For: 25 June By Investing.com - Investing.com South Africa
Royalty Pharma EVP Hite sells $8.16m in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares - MarketBeat
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan - Stock Titan
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX) - TradingView
RPRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 24 June By Investing.com - Investing.com Australia
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX) - Stock Titan
Kirr Marbach & Co. LLC IN Acquires Shares of 237,895 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 144 Royalty Pharma PLC For: 23 June By Investing.com - Investing.com South Africa
[144] Royalty Pharma plc SEC Filing - Stock Titan
Look Beyond Market Euphoria After 3 FCF ETFs Rebalanced - ETF Database
Royalty Pharma plc (RPRX) Stock Analysis: Exploring an 11.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Three “Forever Stocks” for the AI Age - InvestorPlace
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dorsey Asset Management LLC Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Delta Global Management LP Acquires Shares of 44,314 Royalty Pharma PLC $RPRX - MarketBeat
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report - Stock Titan
L2 Asset Management LLC Has $5.63 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 31,091 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Bought by Entropy Technologies LP - MarketBeat
Fieldview Capital Management LLC Invests $3.74 Million in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Raises Stake in Royalty Pharma PLC $RPRX - MarketBeat
Rhenman & Partners Asset Management AB Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
This Royalty Pharma Insider Reduced Their Stake By 10% - Yahoo Finance
Heartland Advisors Inc. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
TD Asset Management Inc Has $9.19 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
CenterBook Partners LP Has $2.71 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04 - marketscreener.com
RPRX: Synthetic royalties and R&D partnerships drive growth, with China and large pharma as key opportunities - TradingView
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
RPRX Q1 2026 Earnings: EPS Surpasses Estimates by 5.11%, Stock SlipsEarnings Stability Report - newsline.com
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
자본화:
|
볼륨(24시간):